/NOT FOR DISTRIBUTION IN THE UNITED STATES OR THROUGH UNITED STATES WIRE SERVICES/
TORONTO, Feb. 5, 2014 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") is pleased to announce that Biosign will once again support the Canadian Heart & Stroke Foundation during "Heart Month".
Specifically, the Company will donate 5% of the net proceeds from each enrollment in the Heart Friendly™ Practice Program to the Heart & Stroke Foundation of Ontario. Additionally, Heart Friendly™ clinicians will be able to distribute timely information from the Heart & Stroke Foundation to their patients along with a Heart Friendly™ Health Report, powered by Biosign.
Biosign offers the Heart Friendly™ Practice program to a variety of Allied Health clinics, including dentists, naturopaths and physiotherapy clinics. Practitioners who enroll in the Heart Friendly™ program typically purchase a Biosign Pulsewave® monitor for each exam room or dental hygiene station, and then also pay a monthly or annual fee for Biosign's Cloud Diagnostics® readings and a free, printable Heart Friendly™ Health Report that they can print for each patient to take home. Clinicians have commented that the Heart Friendly™ program gives them an additional valuable service to offer their patients, helps them differentiate their practice from their competition, and even assists them in identifying patients at immediate risk who may need medical attention.
Biosign CEO Robert Kaul stated: "We are pleased to have another opportunity to support the important work being done at the Canadian Heart & Stroke Foundation. In 2013, we experienced an enthusiastic response from our clinician customers, who recognize that the Heart Friendly™ Practice Program has a positive role to play in the promotion of heart for health. Biosign is proud to report that since inception, the Heart Friendly™ Program has screened over 53,000 Torontonians, while overall, our Pulsewave® solution has taken over 150,000 readings in clinical service."
Other News: Addition to the Management Information Circular of January 10, 2014
This notice will serve as an addition to the biography of slated board director candidate Mr. John-Peter Bradford (see "Particular Matters to be Acted Upon", Section II, Note 3 on page 5 of the MIC): "During the period November 30, 2009 to June 15, 2011, Mr. Bradford served as a Board Member and Chief Restructuring Advisor for Cryptometrics Canada Inc. (CCI) and for Cryptometrics Inc. (CI), a US company. CCI completed a Proposal in Canada and CI completed a Chapter 11 bankruptcy in the United States. He is a member of boards of the resultant companies, which were successfully restructured and funded during his directorship."
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, software enabled health information solutions including the Pulsewave® Health Monitor and the Healthanywhere™ Patient monitoring / self-management platform. The Company's Pulsewave® Health Monitor solution enables pulse wave data collection for cardiovascular clinical decision support and self-care, while its Healthanywhere™ solution offers industry-leading remote patient monitoring and patient centred care management. The Company also offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Practice, Heart Friendly™ Dentist, and Heart Friendly™ Fitness. For more information on Biosign, please visit www.biosign.com.
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
For further information:
Chief Executive Officer
Phone: (416) 218-9800 ext. 201